Abstract
Interleukin-12 receptor beta-1 (IL-12Rbeta1) defect is generally associated with selective susceptibility to weakly pathogenic mycobacteria and Salmonella species. Patients rarely experience infections caused by other organisms. We report a 5-year-old patient with IL-12Rbeta1 deficiency who developed recurrent visceral leishmaniasis 6 months apart. The patient responded to lyposomal amphotericin B treatment reasonably well.
MeSH terms
-
Amphotericin B / therapeutic use
-
Anti-Infective Agents / therapeutic use
-
Antiprotozoal Agents / therapeutic use
-
Child, Preschool
-
Ciprofloxacin / therapeutic use
-
Genetic Predisposition to Disease*
-
Humans
-
Leishmaniasis, Visceral / drug therapy
-
Leishmaniasis, Visceral / genetics*
-
Leishmaniasis, Visceral / immunology*
-
Leishmaniasis, Visceral / prevention & control
-
Male
-
Receptors, Interleukin-12 / deficiency*
-
Receptors, Interleukin-12 / genetics
-
Receptors, Interleukin-12 / metabolism
-
Recurrence
-
Salmonella Infections / drug therapy
-
Salmonella Infections / genetics
-
Salmonella Infections / immunology
Substances
-
Anti-Infective Agents
-
Antiprotozoal Agents
-
IL12RB1 protein, human
-
Receptors, Interleukin-12
-
liposomal amphotericin B
-
Ciprofloxacin
-
Amphotericin B